Agency Business briefs: October 2012

Share this article:
David Zaritsky
David Zaritsky

Roska Healthcare Advertising beefed up its staff by 10—a 20% increase—to accommodate the Astellas business the shop won. Astellas named Roska agency of record for consumer on the firm's Vesicare follow-on for overactive bladder, Myrbetriq (mirabegron). The team will be led by SVP Kimberly Clotman. The agency named Dave Zaritsky (pictured) president in April, and Jay Bolling remains CEO.

Pacific Communications was named agency of record for Kimberly-Clark Health Care unit I-Flow Corp.'s On-Q product line of drug delivery, post-surgical pain relief and site care products to US healthcare professionals and potential patients.

Havas Worldwide Health named Ben Davies CEO of its European division. He replaces Ed Stapor in that role and will report into New York-based managing partners and co-CEOs Doug Burcin and Donna Murphy. Davies joins Havas from PAN Advertising, where he was CEO.

Rosetta named Tom Adamski president and Mark Taylor COO. The Publicis shop promoted Adamski from chief consumer technology and entertainment officer and Taylor from chief marketing operations officer.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?